Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elevated plasma chromogranin-A concentrations in prostatic carcinoma.

D Kadmon1, T C Thompson, G R Lynch

  • 1Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030.

The Journal of Urology
|August 1, 1991
PubMed
Summary

Plasma chromogranin-A levels were elevated in nearly half of patients with advanced prostate cancer. This suggests chromogranin-A may help monitor the disease

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Periprostatic adipose inflammation is associated with high-grade prostate cancer.

Prostate cancer and prostatic diseases·2017
Same author

Updated postoperative nomogram incorporating the number of positive lymph nodes to predict disease recurrence following radical prostatectomy.

Prostate cancer and prostatic diseases·2016
Same author

Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.

Actas urologicas espanolas·2016
Same author

The diffusion of minimally invasive radical prostatectomy in the United States: a case study of the introduction of new surgical devices.

Prostate cancer and prostatic diseases·2014
Same author

DNA damage response and prostate cancer: defects, regulation and therapeutic implications.

Oncogene·2014
Same author

Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression.

British journal of cancer·2013

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Neuroendocrine prostatic carcinoma (NEPC) is a rare but aggressive variant of prostate cancer.
  • Chromogranin-A (CgA) is a known biomarker for neuroendocrine tumors, often assessed via immunohistochemistry in tissue samples.

Observation:

  • This study investigated the utility of plasma chromogranin-A levels as a potential biomarker in patients with advanced prostate cancer.
  • The research focused on patients diagnosed with stage D2 prostate cancer.

Findings:

  • Plasma chromogranin-A levels were found to be elevated in 48% of the 25 patients studied with stage D2 prostate cancer.
  • This indicates a potential correlation between elevated CgA and advanced disease.

Implications:

  • Plasma chromogranin-A may serve as a non-invasive marker for monitoring the clinical progression of prostate cancer.

Related Experiment Videos

  • Further research could validate CgA as a valuable tool in managing patients with advanced prostate cancer, complementing existing diagnostic methods.